What is the 6th Gene Therapy for Ophthalmic Disorders Summit About?
With vision loss progressing rapidly in many eye diseases, and irreversible damage threatening patients with slower-onset conditions, gene therapies represent a critical one-time intervention to preserve sight.
The 6th Gene Therapy for Ophthalmic Disorders Summit brings together the latest breakthroughs driving this urgent field forward. This year’s agenda features exclusive preclinical data from emerging leaders such as Opus Genetics, Coave Therapeutics, and Axovia Therapeutics, alongside 2025 clinical updates from Ocugen, Adverum Biotechnologies, and Beacon Therapeutics.
Don’t miss groundbreaking data reveals and our dedicated focus on securing funding, advancing AAV delivery, and optimizing patient retention strategies - factors that are revolutionizing trial outcomes and shaping regulatory success.
There is a significant unmet need for innovation and curative treatments in ophthalmology. Conferences like this give passionate investors a front-row seat to where breakthroughs are happening, showcasing the progress that brings patients meaningful therapeutic solutions.
James Kasuboski, Partner and Head of Research, Luma Group, 2025 Attendee
Don’t Miss Out On:
Optimizing delivery method selection through comparative analysis of suprachoroidal, subretinal, and intravitreal approaches. Learn from Abeona Therapeutics, Everads Therapy, and Ikarovec’s experiences to identify the most effective administration route for your specific gene therapy application.
Securing funding beyond clinical data requirements with investor-validated strategies. Gain insights from Luma Group on the essential company features that attract investment.
Navigating the dual challenge of endpoint development and validation through collaborative approaches. Join discussions with Beacon Therapeutics and Opus Genetics to optimize secondary endpoint collection, leverage the FDA’s RDEA program, and eliminate confounding variables for approval success.
Accessing real-time clinical trial updates from leading gene therapy developers, including Atsena Therapeutics, Adverum Biotechnologies, and 4D Molecular Therapeutics, to inform your clinical development strategies.
Mastering IND approval processes across different regulatory organizations through data-driven preclinical development approaches, and optimize model selection with insights from Coave Therapeutics, SparingVision, and Axovia Therapeutics.
Who Will You Meet?
This forum is for expert principal scientists, directors, heads, vice presidents and C-level executives across the ophthalmic gene therapy value chain who seek comprehensive industry insights. As the only end-to-end, industry-focused event dedicated to discovering and developing ophthalmic gene therapies, it provides unparalleled case studies and knowledge sharing opportunity to progress this industry.
Explore the Full Event Program
- 6+ Hours of High-Yield Networking with Industry Leaders & Specialized Vendors
- 18 Senior Ophthalmic Gene Therapy Experts Delivering End-to-End Development Expertise
- 50:50 Split Content Focus on Prevalent & Rare Diseases Across 3 Days
Good opportunity to network with others in the field, variety of topics and speakers were enjoyable.
Jennifer Lee, Medical Director, Clinical Development, 4D Molecular Therapeutics, 2024 Attendee
Intimate and great conference with a good mix of preclinical, clinical, regulatory and fundraising topics.
Abraham Scaria, Chief Scientific Officer, Beacon Therapeutics, 2024 Attendee
